RxDoctor Payments Data

Katherine Bennett, MD

Family Medicine · Macclenny, FLNPI 1346792769

Payments from drug & device makers

$821in general payments, 2019–2025

Across 32 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$158
  • AbbVie$149
  • Acelrx Pharmaceuticals, Inc.$109
  • Novo Nordisk$63
  • Sanofi-aventis U.S. LLC$63
  • AstraZeneca$38
  • plus $240 from 11 others

What the payments were for

  • Food & beverage$821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$821 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$38,430
Medicare patients
199
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$29,535
OzempicSemaglutide18$29,082
FarxigaDapagliflozin Propanediol29$27,677
JardianceEmpagliflozin25$27,081
Rosuvastatin Calcium159$1,870
BreynaBudesonide/Formoterol Fumarate11$1,831
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,602
Gabapentin78$1,582
Levothyroxine Sodium129$1,511
Potassium Chloride49$1,310
Atorvastatin Calcium113$1,222
Ezetimibe43$1,065
Amlodipine Besylate164$914
Albuterol Sulfate HfaAlbuterol Sulfate34$828
Sertraline Hcl57$797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$29,53528 claims
Novo NordiskOzempic$63$29,08218 claims
AstraZenecaFarxiga$38$27,67729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Macclenny

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →